CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $49.00 at Stifel Nicolaus

CRISPR Therapeutics (NASDAQ:CRSP) had its target price trimmed by Stifel Nicolaus from $53.00 to $49.00 in a research report report published on Thursday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Several other equities analysts have also recently issued reports on the stock. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday. Bank of America cut their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Chardan Capital lowered their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $74.05.

CRISPR Therapeutics Stock Up 0.4 %

Shares of NASDAQ CRSP opened at $43.49 on Thursday. The firm has a market cap of $3.71 billion, a P/E ratio of -15.37 and a beta of 1.67. CRISPR Therapeutics has a twelve month low of $36.52 and a twelve month high of $91.10. The company has a 50 day moving average of $42.06 and a 200 day moving average of $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. As a group, equities analysts expect that CRISPR Therapeutics will post -5.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several large investors have recently made changes to their positions in CRSP. NewEdge Advisors LLC grew its position in shares of CRISPR Therapeutics by 28.0% during the fourth quarter. NewEdge Advisors LLC now owns 7,420 shares of the company’s stock worth $292,000 after purchasing an additional 1,622 shares in the last quarter. Jump Financial LLC boosted its stake in CRISPR Therapeutics by 174.0% in the 4th quarter. Jump Financial LLC now owns 139,280 shares of the company’s stock worth $5,482,000 after purchasing an additional 88,448 shares during the period. Elkhorn Partners Limited Partnership grew its holdings in CRISPR Therapeutics by 22.6% during the 4th quarter. Elkhorn Partners Limited Partnership now owns 3,800 shares of the company’s stock valued at $150,000 after buying an additional 700 shares in the last quarter. Jaffetilchin Investment Partners LLC raised its position in shares of CRISPR Therapeutics by 56.9% during the fourth quarter. Jaffetilchin Investment Partners LLC now owns 5,208 shares of the company’s stock valued at $205,000 after buying an additional 1,889 shares during the last quarter. Finally, Scotia Capital Inc. lifted its holdings in shares of CRISPR Therapeutics by 11.8% in the fourth quarter. Scotia Capital Inc. now owns 12,295 shares of the company’s stock worth $484,000 after buying an additional 1,300 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.